These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

104 related articles for article (PubMed ID: 19446908)

  • 1. Rapidity of treatment response and outcome in type 1 autoimmune hepatitis.
    Czaja AJ
    J Hepatol; 2009 Jul; 51(1):161-7. PubMed ID: 19446908
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Features associated with treatment failure in type 1 autoimmune hepatitis and predictive value of the model of end-stage liver disease.
    Montano-Loza AJ; Carpenter HA; Czaja AJ
    Hepatology; 2007 Oct; 46(4):1138-45. PubMed ID: 17668882
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Clinical significance of HLA DRB103-DRB104 in type 1 autoimmune hepatitis.
    Montano-Loza AJ; Carpenter HA; Czaja AJ
    Liver Int; 2006 Dec; 26(10):1201-8. PubMed ID: 17105585
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Autoimmune hepatitis in Italy: the Bologna experience.
    Muratori P; Granito A; Quarneti C; Ferri S; Menichella R; Cassani F; Pappas G; Bianchi FB; Lenzi M; Muratori L
    J Hepatol; 2009 Jun; 50(6):1210-8. PubMed ID: 19395113
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Clinical and HLA phenotypes of type 1 autoimmune hepatitis in North American patients outside DR3 and DR4.
    Czaja AJ; Carpenter HA; Moore SB
    Liver Int; 2006 Jun; 26(5):552-8. PubMed ID: 16761999
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Sustained remission after corticosteroid therapy for type 1 autoimmune hepatitis: a retrospective analysis.
    Czaja AJ; Menon KV; Carpenter HA
    Hepatology; 2002 Apr; 35(4):890-7. PubMed ID: 11915036
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Improving the end point of corticosteroid therapy in type 1 autoimmune hepatitis to reduce the frequency of relapse.
    Montano-Loza AJ; Carpenter HA; Czaja AJ
    Am J Gastroenterol; 2007 May; 102(5):1005-12. PubMed ID: 17319926
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Decreased fibrosis during corticosteroid therapy of autoimmune hepatitis.
    Czaja AJ; Carpenter HA
    J Hepatol; 2004 Apr; 40(4):646-52. PubMed ID: 15030981
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Consequences of treatment withdrawal in type 1 autoimmune hepatitis.
    Montano-Loza AJ; Carpenter HA; Czaja AJ
    Liver Int; 2007 May; 27(4):507-15. PubMed ID: 17403191
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Features and consequences of untreated type 1 autoimmune hepatitis.
    Czaja AJ
    Liver Int; 2009 Jul; 29(6):816-23. PubMed ID: 19018980
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Associations between alleles of the major histocompatibility complex and type 1 autoimmune hepatitis.
    Czaja AJ; Strettell MD; Thomson LJ; Santrach PJ; Moore SB; Donaldson PT; Williams R
    Hepatology; 1997 Feb; 25(2):317-23. PubMed ID: 9021941
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Prognostic implications of antibodies to Ro/SSA and soluble liver antigen in type 1 autoimmune hepatitis.
    Montano-Loza AJ; Shums Z; Norman GL; Czaja AJ
    Liver Int; 2012 Jan; 32(1):85-92. PubMed ID: 21745277
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Genetic heterogeneity in susceptibility to autoimmune hepatitis types 1 and 2.
    Bittencourt PL; Goldberg AC; Cançado EL; Porta G; Carrilho FJ; Farias AQ; Palacios SA; Chiarella JM; Abrantes-Lemos CP; Baggio VL; Laudanna AA; Kalil J
    Am J Gastroenterol; 1999 Jul; 94(7):1906-13. PubMed ID: 10406258
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Factors predicting relapse and poor outcome in type I autoimmune hepatitis: role of cirrhosis development, patterns of transaminases during remission and plasma cell activity in the liver biopsy.
    Verma S; Gunuwan B; Mendler M; Govindrajan S; Redeker A
    Am J Gastroenterol; 2004 Aug; 99(8):1510-6. PubMed ID: 15307869
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Frequency of concurrent autoimmune disorders in patients with autoimmune hepatitis: effect of age, gender, and genetic background.
    Bittencourt PL; Farias AQ; Porta G; Cançado EL; Miura I; Pugliese R; Kalil J; Goldberg AC; Carrilho FJ
    J Clin Gastroenterol; 2008 Mar; 42(3):300-5. PubMed ID: 18223493
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Gender effects and synergisms with histocompatibility leukocyte antigens in type 1 autoimmune hepatitis.
    Czaja AJ; Donaldson PT
    Am J Gastroenterol; 2002 Aug; 97(8):2051-7. PubMed ID: 12190176
    [TBL] [Abstract][Full Text] [Related]  

  • 17. HLA-DRB1*010101 allele is closely associated with poor virological response to lamivudine therapy in patients with chronic hepatitis B.
    Jin YJ; Shim JH; Chung YH; Kim JA; Choi JG; Park WH; Lee D; Kim SE; Lee YS; Kim SH; Yang SH
    Digestion; 2011; 84 Suppl 1():35-42. PubMed ID: 22156484
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Ursodeoxycholic acid as adjunctive therapy for problematic type 1 autoimmune hepatitis: a randomized placebo-controlled treatment trial.
    Czaja AJ; Carpenter HA; Lindor KD
    Hepatology; 1999 Dec; 30(6):1381-6. PubMed ID: 10573515
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Genetic contribution of major histocompatibility complex class II region to type 1 autoimmune hepatitis susceptibility in Venezuela.
    Fortes Mdel P; Machado IV; Gil G; Fernández-Mestre M; Dagher L; León RV; Bianco NE; Tassinari P
    Liver Int; 2007 Dec; 27(10):1409-16. PubMed ID: 17927716
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Antibodies to soluble liver antigen/liver pancreas and HLA risk factors for type 1 autoimmune hepatitis.
    Czaja AJ; Donaldson PT; Lohse AW
    Am J Gastroenterol; 2002 Feb; 97(2):413-9. PubMed ID: 11866281
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.